Clinical Trials

Rebiotix has conducted several clinical trials with it’s lead microbiota-based product in the MRT™ drug platform, RBX2660 for the prevention of recurrent Clostridium difficile (C. diff) infection, and is currently enrolling in a Phase 3  clinical trial,  in conjunction with the U.S Food and Drug Administration under an Independent New Drug Application.

For currently enrolling clinical trials, go to clinicaltrials.gov.

Important milestones include:

• PUNCH CD study: Phase 2 multicenter, open-label study. Reported in October 2014.
• PUNCH CD 2: Phase 2B, prospective, multi-center randomized double-blind, placebo-controlled study of a microbiota-based drug. Results reported Q4 2016.
• PUNCH Open Label: Phase 2 prospective, multi-center, open label controlled trial. Topline results reported April 2017.
• Phase 3 PUNCH CD 3 – currently enrolling (click for details). Initiated Q3 2017.
• Acquired by Ferring Pharmaceuticals in April 2018.

Special FDA designations for RBX2660:

• Fast Track – May 2013
• Orphan Drug – March 2014
• Breakthrough Therapy – October 2015